top of page

Peer-Reviewed Journal Publications
(* indicates corresponding author)

21. Jiang, S., Chen, Z., Wu, J., Zang, X., & Jiang, Y.* Addressing Methodological and Ethical Issues in Practicing Health Economic Evaluation in China. Journal of Global Health. (2020). (forthcoming)

 

20. Jiang, Y.* & Ni, W. Impact of supplementary private health insurance on hospitalization and physical examination in China. China Economic Review. (2020). doi: 10.1016/j.chieco.2020.101514

 

19. Jiang, Y.*, Cai, D., Chen, D. & Jiang, S. The cost-effectiveness of conducting three versus two reverse transcription-polymerase chain reaction tests for diagnosing and discharging people with COVID-19: evidence from the epidemic in Wuhan, China. BMJ Global Health. (2020) doi: 10.1136/bmjgh-2020-002690

18. Jiang, Y.* & Ni, W. (2020). Association Between Supplemental Private Health Insurance and Burden of Out-of-Pocket Healthcare Expenditure in China: A Novel Approach to Estimate Two-Part Model with Random Effects Using Panel Data. Risk Management & Healthcare Policy. 2020;13:323-334. doi: 10.2147/RMHP.S223045

17. Papaioannou, A., Adachi, J. D., Berger, C., Jiang, Y.*, Barron, R., McGinley, J. S., ... & Ioannidis, G. (2020). Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study. Osteoporosis International, 1-9. doi: 10.1007/s00198-020-05330-2
 

16. Jiang, Y.* & Ni, W. Risk selection into supplemental private health insurance in China. Health Economics Review. (2019) 9:36. 

15. Jiang, Y.*, Ni, W. & Wu, J.* Cost-effectiveness and Value-based Prices of the 9-valent Human Papillomavirus Vaccine for the Prevention of Cervical Cancer in China: An Economic Modelling Analysis. BMJ Open. (2019) doi: 10.1136/bmjopen-2019-031186 
 

14. Jiang, Y.* & Ni, W. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease. Pharmacoeconomics. 2019 doi: 10.1007/s40273-019-00791-8

 

13. Jiang, Y.*, Ni, W. Factors Related to the Comparative Effectiveness of Clozapine in Patients with Schizophrenia. Journal of Comparative Effectiveness Research. 2018 doi: 10.2217/cer-2018-0096

 

12. Jiang, Y.*, Ni, W. Estimates of Age-specific Diabetes Incidence among Men and Women in China Using Secondary Data Analysis. Diabetic Medicine. 2018 doi: 10.1111/dme.13821 (research letter)

 

11. Jiang, Y.*, McCombs, J. S., & Park, S. H. A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics. CNS drugs 31.4 (2017): 319-326. doi: 10.1007/s40263-017-0421-4 

 

10. Ni, W. & Jiang, Y.* Evaluation on the Cost-effective Threshold of Osteoporosis Treatment on Elderly Women in China Using Discrete Event Simulation Model. Osteoporosis International. 2017 Feb;28(2):529-538. doi: 10.1007/s00198-016-3751-z. 

 

9. Jiang, Y.* & Ni, W. Expected Lifetime Numbers, Risks, and Burden of Osteoporotic Fractures for 50-Year Old Chinese Women— a Discrete Event Simulation Incorporating FRAX. Journal of Bone and Mineral Metabolism. 2016 Nov;34(6):714-722. doi: 10.1007/s00774-015-0724-9. 

 

8. Jiang, Y.* & Ni, W. Healthcare Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment. Journal of Managed Care Pharmacy. 2015 Sep;21(9):780-92. doi: 10.18553/jmcp.2015.21.9.780. 

 

7. Jiang, Y.* & Ni, W. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization. Pharmacotherapy. 35.9 (2015): 813-822. doi: 10.1002/phar.1634. 

 

6. Jiang, Y.*, Ni, W., McGinnis, J. Comparison of Health Services Use Associated with Ziprasidone and Olanzapine among Schizophrenia and Bipolar Disorder Patients in the USA. Clin Drug Investig: 34.7 (2014): 491-499. doi:10.1007/s40261-014-0202-5. 

 

5. Jiang, Y.* & McCombs, J. Improving Model Specifications When Estimating Treatment Effects across Alternative Medical Interventions. Open Journal of Statistics, 4.10 (2014): 857. doi: 10.4236/ojs.2014.410081.

 

4. Trief, P.*, Jiang, Y., Beck, R., Huckfeldt, P., Knight, T., Miller, K., Weinstock, R. Adults with Type 1 Diabetes: Partner Relationships and Outcomes. Journal of Health Psychology. 22.4 (2017): 446-456. doi:10.1177/1359105315605654. 

 

3. Thomas, K.*, Jiang, Y., McCombs, J. Clozapine Revisited: Impact of Clozapine versus Olanzapine on Health Care Use by Medicaid Schizophrenia Patients. Annals of Clinical Psychiatry 27.2 (2015): 90-99. 

 

2. He, X., Wu, J.*, Jiang, Y., Liu, L., Ye, W., Xue, H., & Montgomery, W. Health Care Resource Utilization and Direct Medical Costs for Patients with Schizophrenia Initiating Treatment with Atypical Versus Typical Antipsychotics in Tianjin, China. BMC Health Services Research, 15.1 (2015): 149. doi: 10.1186/s12913-015-0819-y. 

 

1. O'Hanlon, C., Parthan, A., Kruse, M., Cartier, S., Stollenwerk. B., Jiang, Y., Caloyeras, J., Crittenden, B., Barron, R.* A Model for Assessing the Clinical and Economic Benefits of Bone-Forming Osteoporosis Agents in Reducing Fractures in Post-Menopausal Women at High, Near-Term Risk of Fragility Fracture. Clinical Therapeutics 39.7 (2017): 1276-1290. doi: 10.1016/j.clinthera.2017.05.348 

Journal Publication in Chinese

1. Zhang, X., Ni, W., Niu, X., Jiang, Y., & Wu, J. * Economic Evaluation of Baofukang Suppository Versus-2a Interferon Suppository in Cervical Intraepithelial Neoplasia 1. China Journal of Pharmaceutical Economics. 2015(12)

Conference and Other Publications

13. McGinley, J., Ioannidis, G., Kovacs, C., Kaiser, S., Hanley, D., Prior, J., Davison, K., Leslie, W., Morin, S., Jiang, Y. Testing an Evidence-based Theoretical Model of Imminent (1-year) Fracture Risk in Elderly Women: Results from the Canadian Multicentre Osteoporosis Study (CaMos).

ASBMR 2017, Denver, CO, USA

 

12. Jiang, Y., Barron, R., Grauer, A. A Focused Literature Review of the Direct Medical Costs Associated with Clinical Fractures in the United States.

WCO-IOF-ESCEO 2017, Florence, Italy

 

11. Jiang, Y., McCombs, J., Park, S. PMH4 The Impact of Alternative Antipsychotic Medications on the Risk of Adverse Events in Patients Treated for Bipolar Disorders. Value in Health. 2015 May 1 (Vol. 18, No. 3, pp. A115-A115). doi: 10.1016/j.jval.2015.03.676

 

10. Jiang, Y., McCombs, J., Park, S. PMH3 The Impact of Alternative Antipsychotic Medications on the Risk of Adverse Events in Patients Treated for Schizophrenia. Value in Health. 2015 May 1 (Vol. 18, No. 3, pp. A115-A115). doi: 10.1016/j.jval.2015.03.675

 

9. Jiang, Y., McGinnis, J.J., Ni, W. PMH14 Comparison of Medical Costs and Utilization Associated with Use of Ziprasidone and Olanzapine Among Schizophrenia and Bipolar Disorder Patients. Value in Health. 2014 Nov 1;17(7):A768. doi: 10.1016/j.jval.2014.08.297

 

8. He, X., Wu, J., Jiang, Y., Liu, L., Ye, W.Y., Xue, H.B., Montgomery, W. Health care resource utilization and direct medical costs for schizophrenia patients initiating typical or atypical antipsychotics in Tianjin, China. Value in Health. 2014 May 1;17(3):A213. doi: https://doi.org/10.1016/j.jval.2014.03.1248

 

7. Huckfeldt, P., Knight, T., Jiang, Y., Beck, R., Miller, K., Peters, A., Goldman, D., Patient Factors Associated with Setting and Attaining A1c Targets.

American Diabetes Association 2013 73rd Scientific Sessions, Chicago, IL, USA

 

6. Jiang, Y., Huckfeldt, P., Knight, T., Goldman, D. PRM108 Construct validity of the SF-12 in type-1 diabetes. Value in Health. 2013 May 1;16(3):A32. doi: 10.1016/j.jval.2013.03.185

 

5. McCombs, J., Jiang, Y., The Impact of Atypical Antipsychotic Medications on the Use of Health Care by California Medicaid [Medi-Cal] Patients with Schizophrenia Or Bipolar Disorder.

APA 2013 64th Institute on Psychiatric Services, New York, NY, USA

 

4. Jiang, Y., McCombs, J., Impact of Second Generation Anti-psychotics in Bipolar Patients and Schizophrenia Patients in the California Medicaid Program.

WPA International Congress 2012, Prague, Czech Republic

 

3. McCombs, J., Jiang, Y., PMH32 Impact of Second Generation Anti-Psychotics in Bipolar Patients and Schizophrenia Patients in the California Medicaid Program. Value in Health. 2012 Jun 1;15(4):A87. doi: http://dx.doi.org/10.1016/j.jval.2012.03.477

 

2. Jiang, Y., Hay, J., PMS27 The Cost-Effectiveness of Denosumab for the Prevention of Osteoporotic Fractures in the Setting of the United States. Value in Health. 2012 Jun 1;15(4):A38. doi: https://doi.org/10.1016/j.jval.2012.03.216

 

1. Twanmoh, J., Fleming, A.E., Brooks, D., Jiang, Y., Villacorta, R., McCombs, J. PHP53 A Rapid Evaluation Unit Increases Emergency Department Visits. Value in Health. 2011 May 1;14(3):A21. doi: https://doi.org/10.1016/j.jval.2011.02.123

Select submitted and ongoing work

Explain health-related risky behavior with prospect theory and the theory of mental accounting

bottom of page